Vandria
Vandria is an Aging Drug Discovery company founded in 2021 and based in Plan-les-Ouates, Switzerland. It has raised $32M in total funding, most recently a Series A.
Vandria is a clinical-stage Swiss biopharmaceutical company developing small molecules that induce mitophagy, the selective clearance of damaged mitochondria, to restore cellular energy production and reduce chronic inflammation in age-related disease. Led by CEO Dr. Klaus Dugi, the company raised a $32M Series A and advanced its lead candidate VNA-318 into a first-in-human Phase 1 trial, with the program aimed at indications including mild cognitive impairment, Alzheimer's, Parkinson's and major depressive disorder, and described as having both immediate cognitive benefits and long-term disease-modifying potential. Vandria has signaled plans for parallel Phase 2a studies in patient populations, positioning mitochondrial quality control as a lever against the biology of aging.
Vandria is one of the most clinically advanced bets on mitophagy as an aging pathway, testing whether restoring mitochondrial quality can modify age-related disease.
vandria.com ↗·Aging Drug Discovery·
Switzerland·private 
